SCHEMBL3010750

SCHEMBL3010750

COc1cc(Cc2csc(N3CCC(S(=O)(=O)c4ccccc4Cl)CC3)n2)cc(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 3/20 0.40
F2 P00734 5/20 0.39
FAAH O00519 1/20 0.38
EPHX2 P34913 1/20 0.38
MAPT P10636 6/20 0.38
ALDH1A1 P00352 4/20 0.37
LMNA P02545 3/20 0.37
HSD17B10 Q99714 3/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPK1 P28482 2/20 0.37
KCNQ1 P51787 1/20 0.36
CTRC Q99895 2/20 0.36
F10 P00742 1/20 0.36
PRSS2 P07478 1/20 0.36
USP2 O75604 1/20 0.35
RECQL P46063 1/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006777 0.93 MAPT (0.44) CTSSFAAHEPHX2MAPTALDH1A1
SCHEMBL3017549 0.93 CTSS (0.40) CTSSF2MAPTALDH1A1LMNA
SCHEMBL3010492 0.92 CTSS (0.42) CTSSFAAHEPHX2MAPTALDH1A1
SCHEMBL3017410 0.90 MAPT (0.36) F2MAPTALDH1A1LMNAHSD17B10
SCHEMBL2999478 0.90 CTSS (0.36) CTSSF2MAPTALDH1A1LMNA
SCHEMBL3016132 0.90 MEN1 (0.39) CTSSFAAHEPHX2MAPTALDH1A1
SCHEMBL3018818 0.89 TDP1 (0.42) CTSSF2MAPTALDH1A1LMNA
SCHEMBL2997798 0.89 CTSS (0.43) CTSSFAAHEPHX2MAPTLMNA
SCHEMBL3001246 0.89 CTSS (0.35) CTSSF2MAPTALDH1A1LMNA
SCHEMBL3019060 0.89 CTSS (0.43) CTSSMAPTLMNAHSD17B10RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885F2 4807/4885FAAH 3111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.